Literature DB >> 6088932

Bidentate peptides: highly potent new inhibitors of enkephalin degrading enzymes.

R Bouboutou, G Waksman, J Devin, M C Fournié-Zaluski, B P Roques.   

Abstract

Three series of bidentates bearing an hydroxamic or an N-Acyl-N-hydroxy amino group on structures related to Phe-Gly or Phe-Ala exhibit strong inhibitory potency against purified enkephalinase with IC50 values in the 4 to 15 nM range. As with thiol-containing inhibitors, such as thiorphan, the most active compounds are those in which a methylene spacer separates the benzyl P1' moiety from the Zn coordinating residue. Formation of a bidentate complex with the metal enzyme is clearly demonstrated by a loss of potency of three order of magnitude following the removal of one component of the bidentate group. All the compounds studied are unable to interact with angiotensin converting enzyme (IC50 greater than 10,000 nM). Moreover, compounds of the general formula HONHCO-CH2-CH(CH2 phi)-CONH-CH(R)-COOH belonging to the most active series of enkephalinase blockers (IC50 approximately 4 nM) behave also as highly potent and competitive inhibitors (IC50 approximately 10 nM) of a Tyr-Gly releasing dipeptidylaminopeptidase purified from rat brain. The pure steroisomer [(R)-3-(N-hydroxy)carboxamido-2-benzylpropanoyl]-L-alanine designated kelatorphan, exhibits also a relatively good inhibitory potency against aminopeptidases (IC50 approximately 10 microM) and can be considered as the first virtually complete inhibitor of enkephalin metabolism. This very interesting property of inhibiting all three enzymes of enkephalin metabolism could enhance the required selectivity for a possible clinical use of these inhibitors as new analgesic and psychoactive drugs.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6088932     DOI: 10.1016/0024-3205(84)90669-6

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  7 in total

1.  Attenuation of the morphine withdrawal syndrome by inhibition of catabolism of endogenous enkephalins in the periaqueductal gray matter.

Authors:  R Maldonado; M C Fournié-Zaluski; B P Roques
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1992-04       Impact factor: 3.000

2.  Effect of endopeptidase-24.11 inhibitors and C-ANP receptor ligand on responses evoked in arterioles of rat cremaster muscle by atrial natriuretic peptide.

Authors:  J Peyroux; F Beslot; N Claperon; M C Fournie-Zaluski; B P Roques
Journal:  Br J Pharmacol       Date:  1995-12       Impact factor: 8.739

3.  Autoradiographic comparison of the distribution of the neutral endopeptidase "enkephalinase" and of mu and delta opioid receptors in rat brain.

Authors:  G Waksman; E Hamel; M C Fournié-Zaluski; B P Roques
Journal:  Proc Natl Acad Sci U S A       Date:  1986-03       Impact factor: 11.205

4.  Dopamine depletion augments endogenous opioid-induced locomotion in the nucleus accumbens using both mu 1 and delta opioid receptors.

Authors:  L Churchill; B P Roques; P W Kalivas
Journal:  Psychopharmacology (Berl)       Date:  1995-08       Impact factor: 4.530

5.  Calcitonin gene-related peptide elevates cyclic AMP levels in chick skeletal muscle: possible neurotrophic role for a coexisting neuronal messenger.

Authors:  R Laufer; J P Changeux
Journal:  EMBO J       Date:  1987-04       Impact factor: 11.598

6.  Binding properties of a highly potent and selective iodinated aminopeptidase N inhibitor appropriate for radioautography.

Authors:  F Noble; N Luciani; S Da Nascimento; R Laï-Kuen; L Bischoff; H Chen; M C Fournié-Zaluski; B P Roques
Journal:  FEBS Lett       Date:  2000-02-04       Impact factor: 4.124

7.  Design of the first highly potent and selective aminopeptidase N (EC 3.4.11.2) inhibitor.

Authors:  H Chen; B P Roques; M C Fournié-Zaluski
Journal:  Bioorg Med Chem Lett       Date:  1999-06-07       Impact factor: 2.823

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.